Class III โ€” Low Risk

Low risk โ€” use of or exposure to this product is not likely to cause adverse health consequences.

Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen) Recalled by Teva Pharmaceuticals USA, Inc Due to Discoloration: discolored tablets (shades of blue) mixed in...

Date: January 25, 2024
Company: Teva Pharmaceuticals USA, Inc
Status: Ongoing
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Teva Pharmaceuticals USA, Inc directly.

Affected Products

Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), packaged in cartons, each carton contains 6 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9012-58

Quantity: 19,824 cartons

Why Was This Recalled?

Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

Where Was This Sold?

This product was distributed nationwide across all 50 states.

Affected (51 states)Not affected

About Teva Pharmaceuticals USA, Inc

Teva Pharmaceuticals USA, Inc has 20 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report